BioLineRx Ltd. BLRX
1.58 USD -0.15 (-8.67%)
At closeNov 9, 2026, 4:00 PM EST
1.70 +0.12 +7.59%
After hours · Nov 9, 4:00 PM ET
1.58 Day range 1.71
1.58 52-week range 3.95
- YTD
- -42.96%
- 1 year
- -51.68%
News
benzinga.com BioLineRx And Hemispherian Present Data At ESMO 2026 Demonstrating Synergy Between GLIX1 And Multiple PARPi In Homologous Recombination-Proficient Ovarian Cancer Cell Lines And In In Vivo Patient-Derived Xenograft Model GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand…
benzinga.com BioLineRx Announces That Two Abstracts Featuring GLIX1 Will Be Presented At The Society For Neuro-Oncology Annual Meeting, November 12-15 The presentations will highlight preclinical research evaluating GLIX1 across multiple glioblastoma models, as well as the design of the ongoing Phase 1/2a clinical trial evaluating GLIX1 in patients…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre-market session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma…
benzinga.com BioLineRx And Hemispherian To Present Preclinical Efficacy Of GLIX1 In Orthotopic Glioblastoma Models, At 21st Meeting Of EANO 2026 BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON)…
benzinga.com BioLine Rx Q2 Sales $294.000K Miss $500.000K Estimate BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $294.000 thousand which missed the analyst consensus estimate of $500.000 thousand by 41.20 percent. This is a 3.29 percent decrease over sales of…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) stock moved…
benzinga.com BioLineRx Announces $3.75M Registered Direct Offering Of ADSs At $2.78 Each And Concurrent Private Placement Of Warrants For Up To 2M ADSs BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced…- benzinga.com BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October Presentation Details:Title: GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell LinesPresentation #: 1435ePPresentation type:…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Innovative Eyewear (NASDAQ:LUCY)…
- benzinga.com BioLineRx And Hemispherian Announce New Preclinical Data Showing Strong Synergy Between GLIX1 And PARP Inhibitors In Patient-Derived Xenograft Model Of Ovarian Cancer Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com BioLine Rx Q1 Sales $477.000K Beat $343.000K Estimate BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $477.000 thousand which beat the analyst consensus estimate of $343.000 thousand by 39.07 percent. This is a 87.06 percent increase over sales of…- benzinga.com BioLineRx And Hemispherian Announce Two Abstracts Featuring GLIX1 Will Be Published At ASCO 2026 Annual Meeting BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology…
benzinga.com BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.
benzinga.com BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade Gliomas GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment.In a comprehensive pre-clinical program, orally…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announced in September 2025. The patient was dosed at NYU Langone Health under the supervision of Dr.…- benzinga.com BioLineRx Launches First Human Trial For Brain Cancer Drug BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a…
- benzinga.com BioLine Rx Q4 EPADS $(0.34) Beats $(0.54) Estimate, Sales $194.000K Miss $651.598K Estimate BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.54) by 37.04 percent. The company reported quarterly sales of $194.000…
- benzinga.com BioLine Rx Q4 Sales $194.000K Miss $651.598K Estimate BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $194.000 thousand which missed the analyst consensus estimate of $651.598 thousand by 70.23 percent. This is a 98.35 percent decrease over sales…
benzinga.com Earnings Scheduled For March 23, 2026 
benzinga.com Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Arbitrator Issues Final Award To BioLineRx, Denies All Claims By Biokine Therapeutics; Biokine To Pay Expenses And Legal Fees https://ir.biolinerx.com/static-files/e6f7cf56-4605-44e6-8ed9-f0738b67b983
- benzinga.com BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(1.20) by 81.67 percent. This is a 214.29 percent decrease over losses of $(0.07)…
- benzinga.com Earnings Scheduled For November 24, 2025
benzinga.com BioLine Rx's Earnings: A Preview - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com BioLineRx And Hemispherian Establish JV To Develop GLIX1, Oral, Small Molecule Targeting DNA Damage Response In Glioblastoma And Other Cancers - GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only -- FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 --…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com UPDATE: BioLine Rx Q2 EPADS $(1.00) Beats $(1.20) Estimate, Sales $304.000K Miss $924.000K Estimate BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.20) by 16.67 percent. The company reported quarterly sales of $304.000…- benzinga.com Earnings Scheduled For August 14, 2025
- benzinga.com Examining the Future: BioLine Rx's Earnings Outlook
- benzinga.com Where BioLine Rx Stands With Analysts
- benzinga.com HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $26 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $26 price target.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Dow Edges Higher; Dell Shares Fall After Q1 Results 
benzinga.com Why Is Nano-Cap BioLineRx Stock Surging On Friday? BioLineRx shares new data from its Phase 2 pancreatic cancer trial, showing strong response rates and durable outcomes with motixafortide combination.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Nasdaq Down 100 Points; Chicago PMI Dips In May - benzinga.com Jones Trading Upgrades BioLine Rx to Buy, Announces $12 Price Target Jones Trading analyst Justin Walsh upgrades BioLine Rx (NASDAQ:BLRX) from Hold to Buy and announces $12 price target.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket - benzinga.com Market-Moving News for May 30th REGN: -13% | Regeneron shares are trading lower after the company and Sanofi said the AERIFY-1 study met its primary endpoint but the AERIFY-2 study did not. GAP: -18% | Gap shares are trading lower…